Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 13, 2020 - Issue
Submit an article Journal homepage
104
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Successful Deferasirox Rechallenge and Treating Through Reaction in a Patient with Challenge-Proven Mild Immediate Reaction: A Case Report

Mongkhon Sompornrattanaphan1 Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, ThailandORCID Iconhttps://orcid.org/0000-0001-8419-0873View further author information
ORCID Icon,
Thanachit Krikeerati1 Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand;2 Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandView further author information
,
Chamard Wongsa1 Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, ThailandORCID Iconhttps://orcid.org/0000-0002-5721-4881View further author information
ORCID Icon,
Torpong Thongngarm1 Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, ThailandORCID Iconhttps://orcid.org/0000-0002-3182-4614View further author information
ORCID Icon &
Kittika Yampayon3 Adverse Drug Reaction (ADR) Unit, Pharmacy Department, Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7653-7101View further author information
ORCID Icon
Pages 557-561 | Published online: 30 Oct 2020

References

  • Musallam KM, Angastiniotis M, Eleftheriou A, Porter JB. Cross-talk between available guidelines for the management of patients with beta-thalassemia major. Acta Haematol. 2013;130(2):64–73. doi:10.1159/00034573423485589
  • Huang V, Luini C, El-Ali A, Kessabi S. Iron chelation therapy: a review of the literature on the issues and importance of adherence to treatment in iron overload. Blood. 2015;126(23):4748. doi:10.1182/blood.V126.23.4748.4748
  • Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther. 2016;10:465–481. doi:10.2147/DDDT.S79458
  • Chaudhary P, Pullarkat V. Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med. 2013;4:101–110.23966805
  • Bruner KE, White KM. Deferasirox desensitization. J Allergy Clin Immunol Pract. 2016;4(1):171–172. doi:10.1016/j.jaip.2015.09.00726489716
  • Davies GI, Davies D, Charles S, Barnes SL, Bowden D. Successful desensitization to deferasirox in a paediatric patient with beta-thalassaemia major. Pediatr Allergy Immunol. 2017;28(2):199–201. doi:10.1111/pai.1267727797415
  • Tanaka C. Clinical pharmacology of deferasirox. Clin Pharmacokinet. 2014;53(8):679–694. doi:10.1007/s40262-014-0151-424996374
  • Lu MY, Wang N, Wu WH, et al. Simultaneous determination of plasma deferasirox and deferasirox-iron complex using an HPLC-UV system and pharmacokinetics of deferasirox in patients with beta-thalassemia major: once-daily versus twice-daily administration. Clin Ther. 2015;37(8):1751–1760. doi:10.1016/j.clinthera.2015.05.50626093827
  • Chang HH, Lu MY, Liao YM, et al. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia. Pediatr Blood Cancer. 2011;56(3):420–424. doi:10.1002/pbc.2282621072825
  • Isik P, Yarali N, Bay A, Ozmen S, Tunc B. Type-I hypersensitivity reaction secondary to deferasirox intake. Int J Hematol Oncol. 2010;20:42–44.
  • Blanca M, Torres MJ, Garcia JJ, et al. Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics. J Allergy Clin Immunol. 1999;103(5):918–924. doi:10.1016/S0091-6749(99)70439-210329829
  • Kang Y, Kwon OY, Jung H, et al. Breakthrough reactions during rapid drug desensitization: clinical outcome and risk factors. Ann Allergy Asthma Immunol. 2019;123(1):48–56 e41. doi:10.1016/j.anai.2019.05.00731108181

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.